Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting
Ahmed, A., Yousry, W., Abdel-Halim, G., Hashem, W. (2020). Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting. EKB Journal Management System, 81(1), 1281-1284. doi: 10.21608/ejhm.2020.112402
Ahmed ElMetwally Ahmed; Wael Ahmed Yousry; Ghada Kamal Mohamed Abdel-Halim; Walaa Mohammad Hashem. "Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting". EKB Journal Management System, 81, 1, 2020, 1281-1284. doi: 10.21608/ejhm.2020.112402
Ahmed, A., Yousry, W., Abdel-Halim, G., Hashem, W. (2020). 'Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting', EKB Journal Management System, 81(1), pp. 1281-1284. doi: 10.21608/ejhm.2020.112402
Ahmed, A., Yousry, W., Abdel-Halim, G., Hashem, W. Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting. EKB Journal Management System, 2020; 81(1): 1281-1284. doi: 10.21608/ejhm.2020.112402

Clinical Utility of Enzyme-Linked Immunosorbent Assay for Hepatitis C Core Antigen Quantification in Diagnosis and Monitoring Patients Treated with Direct-Acting Antivirals in A Resource Limited Setting

The Egyptian Journal of Hospital Medicine
Article 20, Volume 81, Issue 1, October 2020, Page 1281-1284  XML PDF (433.28 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2020.112402
View on SCiNiTO View on SCiNiTO
Authors
Ahmed ElMetwally Ahmed; Wael Ahmed Yousry; Ghada Kamal Mohamed Abdel-Halim; Walaa Mohammad Hashem*
Gastroenterology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University
Abstract
Background: Hepatitis C virus core antigen (HCV-cAg) assay has been proposed as a more economical alternative to HCV RNA detection. Aim of the work: To evaluate the clinical utility of ELISA for HCV-cAg quantification in diagnosis and monitoring treatment outcomes in patients treated with direct acting antivirals (DAAs) for chronic hepatitis C. Patients and Methods: A prospective study on 40 subjects recruited from hepatology department and outpatient clinic in Ain Shams University Hospitals. Group I included 20 patients with positive anti-HCV antibody. Group II included 20 healthy subjects. The patient group received a combination of sofosbuvir 400 mg and daclatasvir 60 mg once daily for 12 weeks. The levels for both HCV-cAg and HCV RNA were evaluated at baseline and 12 weeks after completion of therapy. Results: Baseline HCV-cAg levels showed good correlation with HCV viral load (r=0.808, p < 0.001). A sustained virological response 12 weeks off therapy (SVR12) was achieved in all patients with HCV-cAg levels decreasing significantly at the end of treatment (EOT) (21.5±8.5 vs 5.4±3.63 IU/ml respectively, p < 0.001). The sensitivity and specificity of HCV-cAg in predicting HCV RNA was 100% and 90% respectively at cut-off value >8 IU/ml. Conclusion: ELISA for HCV-cAg can replace the high sensitivity HCV RNA molecular assay to confirm the presence of HCV infection and to monitor treatment outcome.
Keywords
Hepatitis C virus; HCV-core antigen; HCV RNA, Direct acting antiviral agents
Statistics
Article View: 210
PDF Download: 541